Pelvic Inflammatory Disease: a serious public health issue

Jackie Cassell, Angela Robinson

Introduction

Women present to various doctors, including general practitioners, family planning doctors and hospital specialists, with symptoms that may be due to pelvic inflammatory disease (PID). PID is predominantly a sexually transmitted infection (STI), and the public health implications must be addressed as well as the clinical issues. As in other STIs, at least two people are involved and require investigation and treatment.

Notification and treatment of partners (contact tracing) is the most challenging aspect of good management but is frequently ignored or forgotten. Male partners of women with PID may carry asymptotically *Chlamydia trachomatis* and other bacteria which ultimately may cause complications such as orchitis, epididymitis, urethritis and reactive arthritis.

The definition of PID used by the US Centers for Disease Control (CDC) is "a clinical syndrome resulting from the ascending spread of micro-organisms from the vagina and endocervix to the endometrium, fallopian tubes and/or contiguous structures" (1). This definition is useful in recording acute clinically apparent illness, but it does not include subclinical disease ("silent" PID). Undetected infection such as *Chlamydia trachomatis* ascends from the cervix to the endometrium and/or fallopian tubes, resulting in inflammation and damage to tubal structures, yet produces either no symptoms or only minor, non-specific symptoms which are ignored by women or doctors. An alternative definition which recognises the impact of subclinical disease is offered by Berger *et al*: "An infection which ascends from the lower female genital tract (vagina and cervix) to the level of the fallopian tubes and sometimes their contiguous structures as well (2). With increasing recognition of the importance of silent PID, it is better to use this wider definition.

Epidemiology

Acute PID is a serious and common illness, often requiring hospitalization and sometimes surgery. In the long term, both acute and subclinical PID carry a risk of preventable infertility, ectopic pregnancy

and chronic pelvic pains (3-5). A large follow up study in Sweden demonstrated rates of tubal infertility following single episodes of salpingitis to be 2.6% in mild disease, 13% in moderate disease and 28.6% in severe disease (6). Rates of tubal infertility and ectopic pregnancy increase 2-fold with each new episode of PID (7).

Documenting the epidemiology of PID is problematic. PID is a clinical diagnosis but is notoriously difficult to differentiate from other causes of lower abdominal pain. The clinical criteria for diagnosis have proved hard to validate and are inconsistently applied; the microbial causes vary over time and between populations; women present in a variety of clinical settings with a range of symptoms; and the importance of silent PID as a major public health hazard is becoming increasingly apparent.

In the UK in 1992, 21,168 cases were diagnosed in hospital inpatients (8), and 5735 in Genitourinary medicine clinics (9). Surveillance data from a small but representative sample of general practice for the same year recorded a prevalence of 1.7% in women 16-44 years (10). Calculated over the whole population, this suggests that 165,000 cases of PID would have occurred in women of reproductive age in 1992. Over the last 30 years, there has been an upward trend, as in other developed countries, however unlike some European countries and the USA which have initiated policies to reverse this trend with some success, UK rates continue to increase.

STIs in the armed forces

A retrospective peacetime survey of the British military suggested that the incidence of STIs differed little from that in the civilian population. However, this evidence from 1970-1983 is now outdated (11) and relates only to forces based at home. A study of British forces stationed in the tropics showed a 25-fold increased risk of STI compared with controls in the UK, and recorded 39% of cases as resulting from commercial sex; 70% of those questioned did not normally use a condom (12). Data from US military forces also demonstrate high levels of risky sexual behaviour during postings (13).

Although these data relate to men, their high levels of STI are clearly relevant to the

Dr. Jackie Cassell
MRCP (UK)
Clinical Research Fellow
E-mail:
jcassell@gum.ucl.ac.uk

Dr Angela Robinson
FRCP
Consultant/Honorary
Senior Lecturer GU
Medicine
E-mail:
arobinson@gum.ucl.ac.uk

Dept of STDS
Royal Free and
University College
Medical School

female population with whom these men also have sex. In a prospective American study, 30.3% of military dependent sexually active adolescent females attending for gynaecological examination had an STI (14).

This evidence raises concerns about the acquisition of other STIs and suggests that PID is likely to be a significant health problem in the military, as in other populations. Bacterial STIs are a proven risk factor for HIV transmission (15) and the question of past or ongoing risk of HIV infection should always be considered. In New York, women hospitalized for PID and a seroprevalence for HIV 6.5 times higher than those giving birth in the same hospital (16). In the USA, HIV seroprevalence in women with acute PID ranges from 2.7% to 22% (17).

A review of STI control measures in the US military concludes that screening programmes and collaboration with other government agencies have proved effective, whereas punishment and stigmatization are unhelpful (18). The latter have therefore been abandoned. It is sometimes not fully appreciated that PID is, at least in the majority of cases, a sexually transmitted infection. The same principles must therefore be applied to its management as to other STIs.

Aetiology and pathology.

Berger's definition of PID, cited above, reflects general acceptance that the ascent of bacterial pathogens from the cervix causes most PID. The two major pathogens implicated are *C.trachomatis* and *Neisseria gonorrhoeae*. In the UK, chlamydial infection is more common, with a median prevalence of 4.5% among women of reproductive age attending general practice in the UK (19). In women with acute PID at laparoscopy, 38% had chlamydial infection, 14.4% gonococcal, with dual infection on 7.7% in a recent study (20).

C.trachomatis is an obligate intracellular organism which causes disease by infecting genital mucosal cells. Ciliated cells die, or lose their cilia becoming "clubbed" (21). A process of chronic inflammation ensues, during which *Chlamydiae* may often still be found (22). There is evidence that delayed hypersensitivity occurs, leading to increasingly severe damage with subsequent infections.

PID due to *N.gonorrhoeae* typically results in more severe systemic illness, with the result that women are likely to present earlier with symptoms (23). There is again mucosal damage to the fallopian tubes, but gonococcal infection may also result in septicaemia, septic arthritis and even endocarditis.

In hospitalized cases of PID, at least one STI organism is isolated in 65% of cases

(24). However, in 25-50% of proven PID cases, neither chlamydial or gonococcal infection can be detected (25). Anaerobic or facultative bacteria are found and may have a pathogenic role, although whether as primary or secondary pathogens remains unresolved. *Mycoplasma hominis* has been implicated in the aetiology of PID. *Mycoplasma genitalium* and *Ureaplasma urealyticum* have also been suspected of having a role, but substantive evidence does not exist.

As inflammation continues, microscopic deciliation of the mucosa is compounded by fibrosis and adhesions which distort the anatomy of the upper reproductive tract. The consequent tubal damage results in infertility and ectopic pregnancy; intraovarian pressure may also increase and chronic pelvic pain is a common sequela.

Risk factors and risk variables

Only 10-17% of women infected with *C.trachomatis* or *N.gonorrhoeae* will go on to develop overt PID (26). However *C.trachomatis* has been identified in the upper genital tract of women with no symptoms of abdominal pain who have cervical infection. The causal factors which directly increase risk of developing PID in the presence of an STI are only partially understood. A meta-analysis by Washington *et al* (27) describes risk variables: these reflect numerical risk but it is not clear whether they are true causal factors or confounders.

There is evidence that the following risk variables are associated with PID: young age, single marital status, low socioeconomic status, insertion of an IUCD or other instrumentation in the past 40 days (e.g suction termination of pregnancy, dilatation & curettage), delay in seeking health care, compliance with therapy, smoking, menstruation at the onset of symptoms and douching. A new sex partner in the last month or multiple sexual partners are also associated with increased risk of PID (28). Partner notification and referral should decrease the risk of recurrent PID from reinfection (29). Use of the contraceptive pill is associated with lower risk of symptomatic PID, even though it predisposes the acquisition of *Chlamydia trachomatis*. It is uncertain whether it reduces or increases the risk of silent PID. Medroxyprogesterone acetate (the "Depot" injection) reduces the risk (30).

Increased risk associated with IUCD insertion has now been shown to be low in women at low risk of STIs and to revert to baseline after 40 days (31,32). Moreover, levonorgestrel-medicated IUCDs are associated with a lower risk than copper devices (33). However, instrumentation during termination of pregnancy is dangerous: the median prevalence of

chlamydial infection in women seeking termination of pregnancy in the UK is 8% but under 20's have much higher prevalence (19,34). The incidence of post-abortion PID is 12% (35). Screening for STIs prior to termination of pregnancy has been shown to reduce infection rates and to have cost benefits (36,37).

Diagnosis and differential diagnosis

The clinical diagnosis of PID is unreliable - and the fact that subclinical disease is an important cause of sequelae complicates the picture still further. Even laparoscopy, the "gold standard" since the 1960s has been questioned. In reviewing the current state of diagnosis (38), Kahn *et al* look forward to a diagnostic gold standard which "closely correlates with acute and long term clinical outcomes, assessed with prospective studies".

The clinical picture of PID varies between settings: accident and emergency departments and gynaecologists are likely to see the more systemically ill cases. General practitioners will see women with various presentations but because of insidious disease may fail to consider the diagnosis of PID in women with "non specific" lower abdominal pain.

Symptoms may include abdominal pain (usually bilateral and often for >4 days), intermenstrual bleeding, menorrhagia, preceding vaginal discharge and fever. There may also be urinary tract symptoms, nausea and vomiting.

Classically, the clinical signs of PID are adnexal tenderness and cervical motion tenderness on bimanual pelvic examination. Up to 80% of patients have abnormal vaginal discharge on examination, often purulent, and only 50% have fever.

Laboratory tests, including a raised erythrocyte sedimentation rate, or an increase in C reactive protein, or antichymotrypsin, are significant diagnostic indicators. Similarly, identification of *N.gonorrhoeae* or *C.trachomatis* increases the likelihood of the diagnosis.

None of these symptoms, signs or laboratory tests predict PID well. Researchers have sought to find combinations which give higher sensitivity and specificity. A combination of pelvic pain, adnexal tenderness, temperature >38°C, erythrocyte sedimentation rate >15mm/hr and a palpable mass has a 99% specificity for PID — unfortunately only one sixth of women with PID have all these features (39).

In Scandinavia, diagnostic laparoscopy is undertaken routinely, and this approach has its advocates in the UK. However, even this so-called "gold standard", has limitations. Compared to histological diagnosis on

specimens of fimbrial microbiopsy, the sensitivity of laparoscopy is only 50% and its specificity 80% (40).

The significance of these findings is disputed, but better alternatives have not been established.

No validated, generally accepted algorithm for diagnosis of PID exists as yet. It is therefore important to follow up patients receiving empirical treatment for presumed PID in a few days, to assess the response and reconsider the diagnosis.

The differential diagnosis depends upon the age and sexual history of the patient. The most dangerous missed diagnosis is ectopic pregnancy. A menstrual and sexual history is essential in any woman with abdominal pain. The pregnancy test may be negative in early ectopic pregnancy. Appendicitis, rupture or torsion of an ovarian cyst, endometriosis, urinary tract infection, irritable bowel syndrome and diverticulitis must also be considered. Actinomycosis occasionally gives a picture similar to PID, and the possibility of pelvic tuberculosis should not be forgotten.

Clinical PID is only the tip of the iceberg (41). Silent PID and its consequences can only be addressed at the present time by population measures designed to reduce the incidence and duration of causative STIs. The Centre of Disease Control in USA have recommended screening for *C.trachomatis* in target populations in the wake of evidence that screening can reduce the incidence of overt PID (42,43). Similar recommendations have been made in the UK (19,44).

Management

Delay in seeking medical help increases the probability of complications in PID (45) and a delay of 10 days in therapy increases the risk of subsequent infertility threefold, to 17.8% (46). Delay in offering treatment in a woman who may have PID thus puts her fertility at risk. It is therefore important to start treatment quickly, whether or not laparoscopy is undertaken. A diagnosis of PID should be considered in young sexually active women with abdominal pain, and a low threshold for treatment is essential. Prompt treatment with correct antibiotics protects tubal function.

The objectives of treatment are to resolve inflammation, eradicate infection, preserve fertility, and prevent the complications of ectopic pregnancy and chronic pelvic pain. Initial therapy must cover *N.gonorrhoeae*, *C.trachomatis* and anaerobic bacteria.

Few randomised controlled trials of antibiotic therapy have been undertaken, and those that exist suffer from problems with entry criteria and comparability of populations. A meta-analysis of antimicrobial regimen efficacy has been published (47). The CDC in the USA

advise regimens for inpatient and outpatient treatment as follows (full details are in the reference and on the CDC website) (43).

Intravenous regimen A:

Cefotetan 2g IV 12 hourly or Cefoxitin 2g IV 6 hourly

Plus

Doxycycline 100mg IV or orally every 12 hours.

Intravenous regimen B

Clindamycin 900mg IV every 8 hours

Plus

Gentamicin loading dose IV or IM (2mg/kg body weight) followed by a maintenance dose (1.5mg/kg) every 8 hours. Daily dosing may be substituted.

Parenteral therapy may be changed to oral 24 hours after clinical improvement and oral doxycycline or clindamycin should be continued to a total of 14 days.

Oral regimen A

Ofloxacin 400mg orally, twice daily for 14 days

Plus

Metronidazole 500mg orally twice daily for 14 days

Oral regimen B

Ceftriaxone 250mg IM once

Or

Cefoxitin 2g IM plus Probenecid 1g orally in a single dose concurrently once

Or

Other parenteral third-generation cephalosporin (e.g. ceftizoxime or cefotaxime)

Plus

Doxycycline 100mg orally twice a day for 14 days (included with the above).

These regimes can be expected to be effective in a wide range of settings with differing prevalences of antimicrobial resistance.

Hospital admission for gynaecological assessment should be arranged if a woman has severe symptoms, the diagnosis is in doubt, there is a pelvic mass, or the woman is pregnant. As well as intravenous antibiotic therapy and laparoscopy, laparotomy may be needed for ruptured tubo-ovarian abscess. Other interventions in severe disease include colpotomy, adnexectomy, hysterectomy with salpingo-oophorectomy. Perihepatitis (Fitz-Hugh-Curtis syndrome) should be considered.

If the illness is mild, treatment can be undertaken at home. Basic investigations, including endocervical samples for gonococcal culture and chlamydial antigen detection are nevertheless essential in any woman who may have PID or another sexually transmitted infection. These are usually best undertaken in a genitourinary clinic, where immediate microscopy can be done, but therapy should not be delayed. Sex should be avoided until results of tests are available and adequate therapy has been given to both partners.

If the woman has an IUCD, if there is clinical improvement at 5 days this may be left in place. If it is removed, alternative contraception, and possibly emergency contraception, will need to be discussed.

The patient needs to be reassessed at 5-7 days to ensure that there has been clinical improvement. As well as clinical assessment, her compliance with therapy, partner notification, and information needs should be checked. In published partner

studies for PID, the majority of men have non-specific urethritis, *C. trachomatis* or *N. gonorrhoeae* but are asymptomatic (48,51). It is essential that she understands the importance of partner referral and the need to avoid sexual intercourse until both partners have completed treatment. This should reduce rates of re-infection.

Conclusions

PID is a common sexually transmitted infection which requires early, active treatment to reduce the probability of complications. Partner notification is an essential part of management and can be facilitated by genitourinary clinics, even when treatment is undertaken in primary care. Patients are often unwilling to offer full sexual histories to their primary care doctors, who may in any case not be in a position to offer treatment to all partners. Genitourinary clinics are familiar with these problems and well placed to deal with them.

Standards for partner notification in genital chlamydial infection have recently been published (44), which delineate the essentials of any protocol for ensuring partner notification and treatment compliances. Where treatment is provided outside the genitourinary clinic, adherence to these guidelines will maximise the chances of a good long term clinical outcome.

PID is difficult to diagnose, and often insidious in its presentation: doctors in primary care need to have a high level of suspicion. The financial burden to healthcare providers and personal costs to affected individuals are substantial (52). In Scandinavia, a programme of screening for STIs, together with an education campaign aimed at public and professionals, has been followed by a decrease in PID and ectopic pregnancy rates. Prevention is better than cure: screening for STIs is likely to be effective in military populations.

References

- Centers for Disease Control and Prevention. Case definitions for infectious conditions under public health surveillance. *MMWR* 1997; **46**: RR10 1-55.
- Berger GS, Westrom LV, Wolner-Hanssen P. Definition of pelvic inflammatory disease. In: Berger GS, Westrom LV eds. *Pelvic Inflammatory Disease*. New York NY: Raven Press; 1992: 1-6.
- Patton DL, Moore DE, Spadoni LR *et al.* A comparison of the fallopian tube's response to overt and silent salpingitis. *Obstet Gynecol* 1989; **73**: 662-630.
- Osser S, Persson K, Liedholm P. Tubal infertility and silent chlamydial salpingitis. *Hum Reprod* 1989; **4**: 280-284.
- Westrom LV, Berger GS. Consequences of pelvic inflammatory disease. In: Berger GS, Westrom LV eds. *Pelvic Inflammatory Disease*. New York NY: Raven Press; 1992: 101-114.
- Westrom L. Effect of acute pelvic inflammatory disease on fertility. *Am J Obstet Gynecol* 1993; **169**: 1143-1149.
- Westrom L. Incidence, prevalence, and trends of acute pelvic inflammatory disease and its

- consequences in industrialized countries. *Am J Obstet Gynecol* 1980; **138**: 880-892.
8. Department of Health. *Hospital Episode Statistics*. London: HMSO 1994.
 9. Statistical Bulletin. *New cases seen at NHS Genitourinary Medicine clinics in England 1991/2*. London: Department of Health, 1993.
 10. Simms I, Rogers P, Charlett A. The rate of diagnosis of pelvic inflammatory disease in General Practice: England and Wales. *Int J Std & Aids* 1999.
 11. Masterton RG, Striker PW. Sexually transmitted diseases in a British military force in peacetime Europe, 1970-1983. *Genitourinary Medicine* 1988; **64**: 54-58.
 12. Adams EJ, Strike PW, Green AD, Masteron RG. Sexually transmitted diseases in transient British forces in the tropics. *Genitourinary Medicine* 1994; **70**: 94-96.
 13. Malone JD, Hyams KC, Hawkins RE, Sharp TW, Daniell FD. Risk factors for sexually transmitted diseases among deployed US military personnel. *Sexually Transmitted Diseases* 1993; **20**: 294-298.
 14. Getts AG. Sexually transmitted diseases in military dependent adolescent females. *Military Medicine* 1988; **153**: 89-91.
 15. Grosskurth H, Mosha F, Todd J et al. Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised controlled trial. *Lancet* 1995; **346**: 530-536.
 16. Hoegsberg B, Abulafia O, Sedlis A, Feldman J. Sexually transmitted diseases and human immunodeficiency virus infection among women with pelvic inflammatory disease. *Am J Obstet Gynecol* 1990; **163**: 1135-9.
 17. Korn AP, Landers DV. *Pelvic Inflammatory Disease*. New York: Springer-Verlag; 1996. p140.
 18. Emerson LAC. Sexually transmitted disease control in the armed forces, past and present. *Military Medicine* 1997; **162**: 87-91.
 19. *Chlamydia trachomatis*: Summary and conclusions of CMOs Expert Advisory Group. Department of Health, London, 1998.
 20. Bevan CD, Johal BJ, Mumtaz G, Ridgway G, Siddle NC. Clinical, laparoscopic and microbiological findings in acute salpingitis: report on a United Kingdom cohort. *British Journal of Obstetrics and Gynaecology* 1995; **102**: 407-14.
 21. Patton DL. Immunopathology and histopathology and experimental chlamydial salpingitis. *Rev Infect Dis* 1985; **7**: 746-753.
 22. Henry-Suchet J, Utzmann C, De Brux J, Ardois P, Catalan F. Microbiological study of chronic inflammation associated with tubal factor infertility: role of *Chlamydia trachomatis*. *Fertil Steril* 1987; **47**: 274-277.
 23. Wolner-Hanssen P, Eschenback DA, Paavonen J, Thorpe E Jr, Pettinger M, Holmes KK. Acute salpingitis: relationship of manifestations to infection with *Chlamydia trachomatis* or with *Neisseria gonorrhoeae*. In Bowie WR, Caldwell HD, Jones RP et al eds. *Chlamydial Infections: Proceedings of the 7th International Symposium on Human Chlamydial Infections*. Cambridge, England: Cambridge University Press; 1990: 311-314.
 24. Jossens MOR, Schachter J, Sweet RL. Risk factors associated with pelvic inflammatory disease of differing microbial etiologies. *Obstet Gynecol* 1994; **83**: 989-997.
 25. Rice PA, Schachter J. Pathogenesis of pelvic inflammatory disease. *JAMA* 1991; **266**: 2587-2593.
 26. Sweet RL. Diagnosis and management of acute salpingitis. *J Reprod Med* 1977; **19**: 21.
 27. Washington AE, Aral SO, Wolner-Hanssen P, Grimes DA, Holmes KK. Assessing Risk for Pelvic Inflammatory Disease and Its Sequelae. *JAMA* 1991; **266**: 2581-86.
 28. Wolner-Hanssen P, Eschenback DA, Paavonen J et al. Decreased risk of symptomatic pelvic inflammatory disease associated with oral contraceptive use. *JAMA* 1990; **263**: 54-49.
 29. Howell MR, Kassler WJ, Haddix A. Partner notification to prevent pelvic inflammatory disease in women. *Sexually Transmitted Diseases* 1997; **24**: 287-292.
 30. Westrom L, Wolner-Hanssen P. Pathogenesis of pelvic inflammatory disease. *Genitourinary Medicine* 1993; **69**: 9-17.
 31. Grimes DA. Intrauterine devices and pelvic inflammatory disease: recent developments. *Contraception* 1987; **36**: 97-109.
 32. Lee NC, Rubin GL, Borucki R. The intrauterine device and pelvic inflammatory disease revisited: new results from the Women's Health Study. *Obstet Gynecol* 1988; **72**: 1-6.
 33. Luukkainen TJ, Allonen T. Protective effect of intrauterine release of levonorgestrel on pelvic infection: three years comparative experience of levonorgestrel and copper-releasing intrauterine devices. *Obstet Gynecol* 1991; **77**: 261-4.
 34. Bevan CD, Moors A, Saunders NJ. Screening for lower genital tract infection and the selective use of treatment prior to termination of pregnancy. An audit of the update of new guidelines. Abstract in proceedings of RCOG meeting Nov. 1996.
 35. Penney GC. Preventing infective sequelae of abortion. *Human Reproduction* 1997 (Supplement); 107-112.
 36. Blackwell A, Thomas PD, Wareham K, Emery SJ. Health gains from screening for infection of the lower genital tract in women attending for termination of pregnancy. *Lancet* 1993; **342**: 207-210.
 37. Skjeldestad FE, Tuveng J, Solberg AG, et al. Induced abortion: Chlamydia trachomatis and post-abortion complications: a cost-benefit analysis. *Acta Obstet Gynecol Scand* 1988; **67**: 525-529.
 38. Kahn JG, Walker CK, Washington E et al. Diagnosing pelvic inflammatory disease. *JAMA* 1991; **266**: 2594-2604.
 39. Westrom L. Clinical manifestations and diagnosis of pelvic inflammatory disease. *J Reprod Med* 1983; **28 (suppl)**: 703-708.
 40. Sellors J, Mahony J, Goldsmith C et al. The accuracy of clinical findings and laparoscopy in pelvic inflammatory disease. *Am J Obstet Gynecol* 1991; **164**: 113-120.
 41. Wolner-Hanssen P. Diagnosis of pelvic inflammatory disease. In: Landers DV, Sweet RL, eds. *Pelvic Inflammatory Disease*. New York: Springer-Verlag; 1996. P60.
 42. Scholes D, Stergachis A, Heidrick FE, Andrilla H, Holmes KK et al. Prevention of pelvic inflammatory disease by screening for cervical Chlamydial infection. *NEJM* 1996; **334**: 1362-1366.
 43. 1998 Guidelines for the treatment of sexually transmitted diseases. *MMWR* 1998; Vol 47 (RR-1): 1-111.
 44. Central Audit Group in Genitourinary Medicine. *Clinical Guidelines and Standards for Genital Chlamydial Infection*. Health Education Authority 1998.
 45. Buchan H, Vessey M, Goldacre M, et al. Morbidity following pelvic inflammatory disease. *Br J Obstet Gynaecol* 1993; **100**: 558-562.
 46. Hillis SD, Joesoef R, Marchbanks PA et al. Delayed care for pelvic inflammatory disease as a risk factor for impaired fertility. *Am J Obstet Gynecol* 1993; **168**: 1503-1509.
 47. Walker CK, Kahn JG, Washington AE, Peterson HB, Sweet RL. Pelvic inflammatory disease: metaanalysis for antimicrobial regimen efficacy. *Journal of Infectious Diseases* 1993; **168**: 969-978.
 48. Scott GR, Thompson C, Smith IW and Young H (1989). Infection with *Chlamydia trachomatis* and *Neisseria gonorrhoeae* in women with lower abdominal pain admitted to a gynaecology unit. *British Journal of Obstetrics and Gynaecology* **96**: 473-477.
 49. Jacob M, Shahmanesh M, Whatley J and Thin N. A

- forgotten factor in pelvic inflammatory disease: infection in the male partner. *British Medical Journal* 1987; **294**: 869.
50. Kamwendo FW, Johansson E, Moi H, Forstine L and Danielsson D. Gonorrhoea, genital chlamydial infection and non-specific urethritis in male partners of women hospitalised and treated for acute pelvic inflammatory disease. *Sexually Transmitted Diseases* 1993; **20**: 143-146.
51. Kinghorn G, Hafiz BI and Duerden S. Clinical and microbiological investigation of women with acute salpingitis 1 and their consorts. *British Journal of Obstetrics and Gynaecology* 1986; **93**: 869-880.
52. Washington AE, Katz P. Cost of and payment source for pelvic inflammatory disease. Trends and projections, 193 through 2000 [see comments]. *JAMA* 1991; **266**: 2565-2569.